AM Biotechnologies develops DNA-based affinity agents called thioaptamers using unique chemistries and a proprietary bead-based selection process. Antibodies are currently the most widely-used affinity agents but they are produced in animals, are easily degraded, are expensive to produce, and suffer from batch-to-batch variability. In contrast, thioaptamers are chemically synthesized; they are stable in ambient environments with very long shelf life; and are rapidly produced in large quantities with easy quality control. AM Biotechnologies solves the problems associated with antibodies while delivering the same functionality. Thioaptamers can be substituted for antibodies in virtually any application. The firm can develop thioaptamer affinity agents using bead-based development service. AM also offers DNA thiophosphoramidite reagents via a strategic partnership with Glen Research Corporation and the RNA thiophosphoramidites are near market introduction. These unique reagents are used to synthesize thioaptamers and are also highly useful for providing in vivo stability and increased potency in RNAi applications.